Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Income from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)
Others
Ratios

Fate Therapeutics (FATE) EBT (2016 - 2025)

Historic EBT for Fate Therapeutics (FATE) over the last 14 years, with Q3 2025 value amounting to -$32.2 million.

  • Fate Therapeutics' EBT rose 3291.47% to -$32.2 million in Q3 2025 from the same period last year, while for Sep 2025 it was -$162.0 million, marking a year-over-year increase of 936.93%. This contributed to the annual value of -$193.0 million for FY2024, which is 1134.46% down from last year.
  • Fate Therapeutics' EBT amounted to -$32.2 million in Q3 2025, which was up 3291.47% from -$34.0 million recorded in Q2 2025.
  • In the past 5 years, Fate Therapeutics' EBT ranged from a high of -$24.9 million in Q1 2023 and a low of -$84.6 million during Q3 2022
  • Moreover, its 5-year median value for EBT was -$46.9 million (2024), whereas its average is -$52.0 million.
  • As far as peak fluctuations go, Fate Therapeutics' EBT plummeted by 10901.28% in 2021, and later surged by 6637.63% in 2023.
  • Over the past 5 years, Fate Therapeutics' EBT (Quarter) stood at -$69.1 million in 2021, then grew by 10.92% to -$61.5 million in 2022, then grew by 29.05% to -$43.7 million in 2023, then plummeted by 32.55% to -$57.9 million in 2024, then skyrocketed by 44.43% to -$32.2 million in 2025.
  • Its last three reported values are -$32.2 million in Q3 2025, -$34.0 million for Q2 2025, and -$37.9 million during Q1 2025.